Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis

Background and aims: Ulcerative colitis (UC) is characterised by refractory inflammatory ulceration and damage to the colon. The mechanisms underlying impaired healing have yet to be defined. As transglutaminase expression resulting in matrix protein cross linking is associated with increased wound healing in a rat model of colitis, we hypothesised that different types of transglutaminase might also play a role in UC. Patients and methods: Endoscopic and histological indices were studied in 26 patients with UC (10 active and 16 inactive) and in 20 normal controls undergoing colonoscopy. Transglutaminase activity was evaluated in plasma (factor XIIIa) by a radioenzymatic method. Factor XIIIa, tissue and keratinocyte transglutaminase protein content, and mRNA expression in the colon were evaluated by western blot analysis and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), respectively. Colonic location of transglutaminases and their reaction products, the ε-(γ-glutamyl)lysine bonds, was evaluated by immunohistochemistry using specific monoclonal antibodies. Results: Transglutaminase activity was significantly lower in the plasma of patients with active UC (4.2 (2.4) mU/ml; p<0.05 v controls) than in those with inactive UC and controls (10.6 (2.2) and 12.1 (1.7) mU/ml). As shown by western blot, protein levels of tissue transglutaminase and factor XIIIa were unchanged in active UC compared with inactive disease and controls, while the keratinocyte form was reduced in active UC. Tissue transglutaminase and factor XIIIa immunostaining was strongly present in damaged areas colocalising with isopeptide bonds. In contrast, the keratinocyte form was almost absent in active UC and localised in the upper part of the crypts in normal subjects. RT-PCR showed upregulation of tissue transglutaminase mRNA in active UC (320% compared with controls) while keratinocyte transglutaminase gene expression was downregulated in active UC. Conclusions: The results of the present study support the concept that, in the damaged colon, transglutaminases are needed in response to chronic injury and underline the key role of these enzymes in mucosal healing.

[1]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[2]  E. Mazzon,et al.  Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat , 2001, Gut.

[3]  A. Grossman,et al.  Recombinant Factor XIII Improves Established Experimental Colitis in Rats , 2000, Digestive Diseases and Sciences.

[4]  D. Aeschlimann,et al.  Cell Surface Localization of Tissue Transglutaminase Is Dependent on a Fibronectin-binding Site in Its N-terminal β-Sandwich Domain* , 1999, The Journal of Biological Chemistry.

[5]  G. Johnson,et al.  Tissue Transglutaminase Is an In Situ Substrate of Calpain: Regulation of Activity , 1998, Journal of neurochemistry.

[6]  R. Ádány,et al.  Identification of Cytoplasmic Actin as an Abundant Glutaminyl Substrate for Tissue Transglutaminase in HL-60 and U937 Cells Undergoing Apoptosis* , 1997, The Journal of Biological Chemistry.

[7]  J. Takagi,et al.  Dual functions of transglutaminase in novel cell adhesion. , 1996, Journal of cell science.

[8]  Z. Nemes,et al.  Transglutaminase induction by various cell death and apoptosis pathways , 1996, Experientia.

[9]  Soo-Youl Kim,et al.  The Transglutaminase 1 Enzyme Is Variably Acylated by Myristate and Palmitate during Differentiation in Epidermal Keratinocytes* , 1996, The Journal of Biological Chemistry.

[10]  Y. Itoh,et al.  Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond. , 1996, Biochemistry.

[11]  K. Achyuthan,et al.  Hierarchies in the binding of human factor XIII, factor XIIIa, and endothelial cell transglutaminase to human plasma fibrinogen, fibrin, and fibronectin , 1996, Molecular and Cellular Biochemistry.

[12]  L. Franco,et al.  Core Histones Are Glutaminyl Substrates for Tissue Transglutaminase* , 1996, The Journal of Biological Chemistry.

[13]  M. Adolphe,et al.  Type II transglutaminase expression in rabbit articular chondrocytes in culture: relation with cell differentiation, cell growth, cell adhesion and cell apoptosis. , 1996, Biochimica et biophysica acta.

[14]  P. Steinert,et al.  Inactive zymogen and highly active proteolytically processed membrane-bound forms of the transglutaminase 1 enzyme in human epidermal keratinocytes. , 1996, Biochemical and biophysical research communications.

[15]  M. Moghadasian,et al.  Gender-related regional antioxidant profiles in the gastrointestinal tract of the rat , 1996, Molecular and Cellular Biochemistry.

[16]  N. Nakagawa,et al.  Hepatocyte growth factor induces transglutaminase activity that negatively regulates the growth signal in primary cultured hepatocytes. , 1996, Experimental cell research.

[17]  F. D'armiento,et al.  Transglutaminases in Crohn's disease. , 1995, Gut.

[18]  P. Steinert,et al.  Highly Active Soluble Processed Forms of the Transglutaminase 1 Enzyme in Epidermal Keratinocytes (*) , 1995, The Journal of Biological Chemistry.

[19]  M. Paulsson,et al.  Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: identification of osteonectin as a major glutaminyl substrate , 1995, The Journal of cell biology.

[20]  M. Mendelsohn,et al.  Specific binding of the transglutaminase, platelet factor XIII, to HSP27. , 1994, The Journal of biological chemistry.

[21]  R. Graham,et al.  Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. , 1994, Science.

[22]  A. Mukherjee,et al.  Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. , 1994, Journal of biochemistry.

[23]  F. D'armiento,et al.  Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity. , 1994, Gastroenterology.

[24]  T. Kirchner,et al.  Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. , 1992, Gastroenterology.

[25]  M. Paulsson,et al.  Cross-linking of laminin-nidogen complexes by tissue transglutaminase. A novel mechanism for basement membrane stabilization. , 1991, The Journal of biological chemistry.

[26]  J. Kłoczko,et al.  Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis. , 1991, American Journal of Gastroenterology.

[27]  D. Hohl,et al.  Characterization of human loricrin. Structure and function of a new class of epidermal cell envelope proteins. , 1991, The Journal of biological chemistry.

[28]  M. Cardinali,et al.  Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells. , 1990, Cancer research.

[29]  G. Mazzacca,et al.  Serum transglutaminase in inflammatory bowel diseases. , 1990, Journal of clinical gastroenterology.

[30]  S. Thacher Purification of keratinocyte transglutaminase and its expression during squamous differentiation. , 1989, The Journal of investigative dermatology.

[31]  B. Shroot,et al.  Transglutaminases in normal and transformed human keratinocytes in culture. , 1988, The Journal of investigative dermatology.

[32]  N. Parenteau,et al.  Induction of keratinocyte type-I transglutaminase in epithelial cells of the rat. , 1986, Differentiation; research in biological diversity.

[33]  T. Peters,et al.  Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. , 1985, Clinical science.

[34]  R. Rice,et al.  Keratinocyte-specific transglutaminase of cultured human epidermal cells: Relation to cross-linked envelope formation and terminal differentiation , 1985, Cell.

[35]  D. Mosher,et al.  Binding and factor XIIIa-mediated cross-linking of a 27-kilodalton fragment of fibronectin to Staphylococcus aureus. , 1980, Science.

[36]  H. Green,et al.  Presence in human epidermal cells of a soluble protein precursor of the cross-linked envelope: Activation of the cross-linking by calcium ions , 1979, Cell.

[37]  H. Green,et al.  The cornified envelope of terminally differentiated human epidermal keratinocytes consists of cross-linked protein , 1977, Cell.

[38]  L. Lorand,et al.  A filter paper assay for transamidating enzymes using radioactive amine substrates. , 1972, Analytical biochemistry.

[39]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[40]  J. Rothnagel,et al.  Trans glutaminase-mediated cross-linking in mammalian epidermis , 2004, Molecular and Cellular Biochemistry.

[41]  G. Melino,et al.  Assays for transglutaminases in cell death. , 2000, Methods in enzymology.

[42]  M. Paulsson,et al.  Tissue Transglutaminase and Factor XIII in Cartilage and Bone Remodeling , 1996, Seminars in thrombosis and hemostasis.

[43]  F. Baldassarre,et al.  Serum and tissue transglutaminase correlates with the severity of inflammation in induced colitis in the rat. , 1992, Scandinavian journal of gastroenterology.

[44]  M. Classen,et al.  Substitution of factor XIII: a therapeutic approach to ulcerative colitis. , 1991, Haemostasis.

[45]  C. Ciacci,et al.  Transglutaminase activity along the rat small bowel and cellular location. , 1988, Enzyme.

[46]  L. Fésüs,et al.  Kinetic determination of blood coagulation Factor XIII in plasma. , 1985, Clinical chemistry.

[47]  Seung K. ChangS Cellular Transglutaminase THE PARTICULATE-ASSOCIATED TRANSGLUTAMINASE FROM CHONDROSARCOMA AND LIVER PARTIAL PURIFICATION AND CHARACTERIZATION , 2022 .